PhilClapharma SRL
PhilClapharma reported total assets of 867,932 € at the end of the 2025 financial year (annual accounts filed with the NBB on 29 Jun 2026).
The score of PhilClapharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +44 % Total assets +3 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
PhilClapharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 18,464 € | ||||
| Equity | 338,220 € | ||||
| Cash | 9,009 € | ||||
| EBITDA | 53,024 € | ||||
| Total assets | 867,932 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 29 Jun 2026
- Year ended 31 Dec 2024filed on 28 Jun 2025
- Year ended 31 Dec 2023filed on 24 Jun 2024
- Year ended 31 Dec 2022filed on 28 Aug 2023
- Year ended 31 Dec 2021filed on 13 Jul 2022
PhilClapharma's financial analysis
- Solvency39.0%sector median: 44.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of PhilClapharma
PhilClapharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0675.782.469
- VAT number
- BE0675782469
- Peppol
- Registered · 0208:0675782469 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 17 May 2017
- Registered office
- 3080 Tervuren
- Latest accounts
- 2025 · filed on 29 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
PhilClapharma (SRL) has been based in Tervuren since 2017, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 18,464 € and equity of 338,220 €; its revenue is not published. Its solvency stands at 39.0%, below the median of its sector (44.0%).
Companies similar to PhilClapharma
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie DE Neef - Duez Retail sale of pharmaceutical products Mons · balance sheet 181,026 €
- Apotheek Baensland Retail sale of pharmaceutical products Sint-Niklaas · balance sheet 866,828 €
- Verkest - Lesage Retail sale of pharmaceutical products Roeselare · balance sheet 845,357 €
- MED-Pharma Retail sale of pharmaceutical products Anderlecht · balance sheet 892,951 €
- Geassocieerde Apotheek VAN Puyvelde Retail sale of pharmaceutical products Antwerp · balance sheet 908,969 €
- Anciaux Retail sale of pharmaceutical products Woluwe-Saint-Pierre · balance sheet 823,388 €
- Cosom Retail sale of pharmaceutical products Genappe · balance sheet 931,343 €
- Cassifarma Retail sale of pharmaceutical products Leuven · balance sheet 942,826 €
Frequently asked questions about PhilClapharma
What is the revenue of PhilClapharma?
PhilClapharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of PhilClapharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0675782469 for PhilClapharma, if the company is VAT-registered. Its company number (CBE) is 0675.782.469.
Where is the registered office of PhilClapharma?
According to the CBE register, the registered office of PhilClapharma is in 3080 Tervuren.
What is the equity of PhilClapharma?
At the close of the 2025 financial year, the equity of PhilClapharma amounts to 338,220 €, a solvency of 39.0% of total assets.
Who manages PhilClapharma?
The register lists 1 active mandates at PhilClapharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of PhilClapharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →